SpectrumX Holdings CEO Damien Hancox joins Proactive Katie Pilbeam in the London studio to talk about the SPC-069 treatment and what the roadmap looks like for releasing to the market.
Initial in-vitro data shows that SPC-069 is 100% effective at neutralising wildtype, Alpha variant and Delta variant forms of COVID-19.
He also talks about their new production facility outside of Manchester which opened in phase one by October, 'on time and on budget'.
Hancox adds how investors can look forward to generating commercial sales revenues in the near term.